Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3335436
Max Phase: Preclinical
Molecular Formula: C110H176N30O28S
Molecular Weight: 2398.87
Molecule Type: Protein
Associated Items:
ID: ALA3335436
Max Phase: Preclinical
Molecular Formula: C110H176N30O28S
Molecular Weight: 2398.87
Molecule Type: Protein
Associated Items:
Canonical SMILES: CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(C)=O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(N)=O
Standard InChI: InChI=1S/C110H176N30O28S/c1-59(2)53-74(96(156)121-62(7)90(150)129-78(57-86(147)148)100(160)134-79(58-141)101(161)133-77(56-66-29-15-12-16-30-66)99(159)132-76(55-65-27-13-11-14-28-65)98(158)128-73(32-18-20-45-112)106(166)140-51-26-38-83(140)107(167)138-49-24-36-81(138)103(163)122-67(89(114)149)40-42-85(145)146)130-92(152)68(31-17-19-44-111)123-91(151)69(33-21-46-119-109(115)116)125-97(157)75(54-60(3)4)131-93(153)70(34-22-47-120-110(117)118)124-94(154)72(43-52-169-10)127-104(164)82-37-25-50-139(82)108(168)87(61(5)6)135-105(165)88(63(8)142)136-95(155)71(39-41-84(113)144)126-102(162)80-35-23-48-137(80)64(9)143/h11-16,27-30,59-63,67-83,87-88,141-142H,17-26,31-58,111-112H2,1-10H3,(H2,113,144)(H2,114,149)(H,121,156)(H,122,163)(H,123,151)(H,124,154)(H,125,157)(H,126,162)(H,127,164)(H,128,158)(H,129,150)(H,130,152)(H,131,153)(H,132,159)(H,133,161)(H,134,160)(H,135,165)(H,136,155)(H,145,146)(H,147,148)(H4,115,116,119)(H4,117,118,120)/t62-,63+,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,87-,88-/m0/s1
Standard InChI Key: STOZZFGUIRPKMF-BACXSTQGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2398.87 | Molecular Weight (Monoisotopic): 2397.2991 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Zhang Z, Lin Z, Zhou Z, Shen HC, Yan SF, Mayweg AV, Xu Z, Qin N, Wong JC, Zhang Z, Rong Y, Fry DC, Hu T.. (2014) Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction., 5 (9): [PMID:25221655] [10.1021/ml500160m] |
Source(1):